Nathan Kakish, MD
Internal Medicine · West Dundee, ILNPI 1518975309
Payments from drug & device makers
Across 568 payments — averaging $70.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Novo Nordisk$2K
- GSK$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$906
- Lilly USA, LLC$585
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$24,50461%
- Travel & lodging$3,4789%
- Food & beverage$11,70629%
- Education$4401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 97 | $30,550 |
| Novo Nordisk | 136 | $2,458 |
| GSK | 72 | $1,164 |
| AstraZeneca | 39 | $1,132 |
| Sanofi-aventis U.S. LLC | 19 | $906 |
| Lilly USA, LLC | 42 | $585 |
| Novartis | 20 | $557 |
| Amarin Pharma, Inc. | 18 | $424 |
| Merck | 21 | $314 |
| Boehringer Ingelheim | 19 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $210 |
| Pfizer | 9 | $168 |
| Medtronic | 1 | $166 |
| Abbott | 3 | $154 |
| Bristol Myers Squibb | 12 | $140 |
| Boston Scientific | 1 | $126 |
| Eisai Inc. | 10 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $101 |
| Sunovion Pharmaceuticals Inc. | 6 | $92 |
| Regeneron Healthcare Solutions, Inc. | 6 | $85 |
| Biohaven Pharmaceuticals, Inc. | 1 | $82 |
| Mylan Specialty L.p. | 5 | $80 |
| AbbVie(2 entities) | 4 | $50 |
| Johnson & Johnson | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $36 |
| Shire North American Group Inc | 2 | $27 |
| Phadia US Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$28,668
- Otezla$246
- RYBELSUS$242
- TOUJEO$233
- TRELEGY ELLIPTA$229
- SOLIQUA 100/33$220
- ENTRESTO$213
- Signia$166
- JETSTREAM SC$126
- STEGLATRO$125
- Wegovy$125
- AREXVY$125
- AIRSUPRA$125
- AIMOVIG$124
- FARXIGA$122
- ZEPBOUND$122
- BREZTRI$119
- MOUNJARO$116
- Ozempic$109
- NURTEC ODT$101
How this compares
$40,126 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $166,072 |
| OzempicSemaglutide | 58 | $102,391 |
| Xigduo XrDapaglifloz Propaned/Metformin | 60 | $74,815 |
| MounjaroTirzepatide | 40 | $72,932 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $45,325 |
| FarxigaDapagliflozin Propanediol | 33 | $40,369 |
| EliquisApixaban | 24 | $35,568 |
| MyrbetriqMirabegron | 29 | $32,076 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $26,761 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $24,261 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 20 | $22,796 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $22,771 |
| JardianceEmpagliflozin | 13 | $20,850 |
| Repatha SureclickEvolocumab | 23 | $17,137 |
| Novolog FlexpenInsulin Aspart | 23 | $8,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $2,458 | $125,18678 claims |
| Lilly USA, LLCMounjaro | $585 | $72,93240 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,132 | $63,14151 claims |
| PfizerEliquis | $168 | $35,56824 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,164 | $33,12438 claims |
| Boehringer IngelheimJardiance, Tradjenta | $271 | $27,52724 claims |
| AbbVieSynthroid | $50 | $1,67930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in West Dundee
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.